A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

In this week's Targeted Pulse, we cover new FDA designations for cancer drugs, advances in targeted therapies, and key ...

A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapy's ...

The HIMALAYA study reveals the STRIDE regimen significantly improves 5-year survival rates in unresectable HCC, redefining ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

New long-term data highlights the effectiveness and safety of ivosidenib with azacitidine for treating IDH1-mutated AML, ...

Jacob Sands, MD, discusses anaging Dato-DXd toxicities like stomatitis, eye irritation, and interstitial lung disease, which ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Nathan Denlinger, DO, MS, discussed bridging therapy and patient barriers to CAR T-cell therapy.

Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a ...

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...